

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
20 September 2007 (20.09.2007)

PCT

(10) International Publication Number
WO 2007/105047 A2

(51) International Patent Classification:
A61B 6/00 (2006.01)

(21) International Application Number:
PCT/IB2007/000506

(22) International Filing Date: 2 March 2007 (02.03.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/780,823 10 March 2006 (10.03.2006) US

(71) Applicant (for all designated States except US): **McGILL UNIVERSITY** [CA/CA]; 1555 Peel Street, 11th Floor, Montréal, Québec H3A 3L8 (CA).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BURNS, David** [US/CA]; 4755, rue St-André, Montréal, Québec H2J 2Z9 (CA). **TROIANI, David** [CA/CA]; 17899 Charles-Munro, Pierrefonds, Québec H9J 3V1 (CA). **DION, Jonathan** [CA/CA]; 2505 Edouard-Montpetit, Apt. 408, Montréal, Québec H3T1J5 (CA).

(74) Agent: **BERESKIN & PARR**; Suite 4000, 40th Floor, 40 King Street West, Toronto, Ontario M5H 3Y2 (CA).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **ULTRASOUND MOLECULAR SENSORS AND USES THEREOF**



(57) Abstract: The present invention relates to the use of polymers as contrast agents for ultrasounds. The idea is to have a molecular imprint in the polymer that is specific for a given molecule or analyte. When that molecule binds to the polymer it induces a conformational change that results in an increase in the ultrasound signal, referred to as a target-bound state. The method can also be used for example for quantitative measurements of analytes.

WO 2007/105047 A2

ULTRASOUND MOLECULAR SENSORS AND USES THEREOF

FIELD OF THE INVENTION

The invention relates to ultrasound based detection and
5 quantification methods as well as compounds useful in the ultrasonic detection of
analytes.

BACKGROUND OF THE INVENTION

Ultrasound has been established in the field of medicine for many
years, mainly used as an imaging method to help monitor the status of a
10 woman's fetus. The term ultrasound can be defined as sound with a frequency
higher than that perceivable by the human ear (a range of roughly 20 Hz to 20
kHz). Medical ultrasound imaging and associated research typically takes place
in the 1 MHz to 10 MHz range.

The first application of this technique in the field of medicine can be
15 attributed to Dr. Karl Theodore Dussik. In 1952, Austria, he pioneered the field of
medical ultrasonics, recounting his work done on transmission ultrasound
through the brain. Professor Ian Donald further explored other applications of this
technique in the late 50's and 60's. After extensive testing on abdominal masses,
he conducted the very first trial of medical ultrasound on a pregnant woman in
20 1958.

Ultrasound techniques for medical applications have become
popular due to the ease of use and non-invasive features. Ensuing years brought
many improvements to the ultrasound probes, enabling higher resolution images.

When ultrasound strikes a surface object, some of it is reflected,
25 scattered, or transmitted through the object, much like light passing through a
lens. This sound is also attenuated when hitting the surface, with higher
frequencies affected more than lower frequencies. Low frequency sounds can
therefore traverse more layers of matter before being attenuated completely.

- 2 -

In medical ultrasonics, ultrasound is created by a transducer, a tiny piezoelectric device mounted inside a probe. When a current is run through this device, it vibrates at a specific frequency, generating ultrasound waves that emanate in the direction of the probe. The probe also doubles as an ultrasonic
5 detector. When ultrasound hits the piezoelectric device, it vibrates and generates a current.

To ensure that high frequency ultrasonic waves propagate through tissue while minimizing attenuation due to striking a surface, clinical ultrasound probes need to be water-coupled to the tissue body being analyzed. This is
10 achieved using an ultrasound gel, a substance rubbed onto the skin of a patient to provide full contact with the ultrasound probe.

An image can be generated from ultrasound by analyzing the reflections once it has propagated through layers of tissue. The time it takes for the reflections to return to the probe indicates the distance which the ultrasound
15 pulse has traveled. Multiple layers of tissue can be perceived by scanning one spot of the body and listening to the multiple reflections returning to the probe. A complete image can also be generated by scanning a section of the body and aligning all the data from the ultrasonic reflections.

The integration of ultrasonic imaging in the field of medicine
20 allowed a step by step approach to prenatal care in the womb. However, this type of imaging does have some drawbacks.

The first is the tradeoff between depth and resolution. As previously stated, lower frequency sounds (longer wavelength) travel deeper into objects, while higher frequencies (shorter wavelength) reveal very fine details, increasing
25 imaging resolution.

To obtain the best possible resolution, it is preferable to use a high frequency ultrasound. However, such high frequency ultrasound is attenuated very quickly and therefore does not penetrate very far into the human body. In

- 3 -

order to traverse several levels of tissue and organs while still providing reasonable imaging capabilities, the frequency must be lowered, thereby sacrificing resolution.

5 The second major limitation relates to the lack of molecular modulation provided by medical ultrasound. Ultrasonic tissue imaging is very effective at illustrating the state of internal body parts as well as fetuses, however no modulation is gained by present methods of ultrasound with respect to the concentration of any specific molecules in the circulation or in tissues or organs. Other more invasive and often less desirable means are used when this
10 modulation is required.

Therefore, there is a need for improved methods of detection using ultrasound devices.

SUMMARY OF THE INVENTION

15 In a broad aspect of the invention there is provided a method for detecting, identifying and quantifying analytes using ultrasound spectral characteristics. The method advantageously provides molecular modulation using ultrasonic probing of samples.

In one embodiment of the invention there is provided a method for ultrasound contrast enhancement, comprising:

20

-providing an ultrasound molecular sensor comprising one or more target binding sites for binding one or more target molecules, the ultrasound molecular sensor having target-bound and target-unbound states wherein binding of the one or more target molecules to the ultrasound molecular sensor
25 causes a modulation in an ultrasound signal;

-contacting the ultrasound molecular sensor with the one or more target molecules to produce ultrasound molecular sensor in the target-bound state; and

- 4 -

-obtaining an ultrasound signal of the target-bound ultrasound molecular sensor at one or more ultrasound frequencies wherein the signal comprises a modulation indicative of the presence of at least one target molecule.

5 In another embodiment there is provided a method for detecting an analyte, comprising:

-contacting the analyte with an ultrasound molecular sensor comprising one or more analyte binding sites for binding one or more analytes, the ultrasound molecular sensor having analyte-bound and analyte-unbound states wherein binding of the one or more analyte to the ultrasound molecular sensor causes a modulation in ultrasound signal;; and

10

-obtaining an ultrasound signal of the analyte-bound state at one or more frequencies wherein the signal comprises modulation indicative of the presence of the analyte.

15

In yet another embodiment there is provided a compound comprising a ultrasound molecular sensor and analyte binding sites coupled to the ultrasound molecular sensor; the compound having target-bound and target-unbound states, wherein the target-unbound state is substantially transparent to ultrasound and the target-bound state is ultrasound sensitive, and wherein the

20

analyte binding sites are in sufficient number for producing a detectable ultrasound signal at characteristic frequencies when molecules of analytes are bound to the analyte binding sites, thereby causing the compound to be in a target-bound state.

25 BRIEF DESCRIPTION OF THE DRAWINGS

Further features and advantages of the present invention will become apparent from the following detailed description, taken in combination with the appended drawings, in which:

Fig. 1 is an N-isopropylacrilamide (NIPA) hydrogel;

Fig. 2 is an illustration of phase transition hydrogel states;

Fig. 3 is a hydrogel nitrogen purging setup;

Fig. 4 is a flow sample cell experiment setup;

5 Fig. 5A and B FTs of reflectance measurements at various temperatures for NIPA;

Fig. 6A and B FTs of transmission measurements at various temperatures for NIPA;

10 Fig. 7A and B FTs of transmission measurements at various temperatures for HPC;

Fig. 8 is a representation of theophylline imprinted NIPA hydrogel;

Fig. 9 is a schematic diagram of NIPA MIP polymer with theophylline.

15 Fig. 10 is a schematic diagram of NIPA MIP polymer without theophylline

Fig. 11 is an aluminum sample cell experiment setup;

Fig. 12 is a sample FT of imprinted NIPA hydrogel with 1,7 μ M theophylline at 32°C;

20 Fig. 13 is a theophylline calibration line at 32°C (A), 42°C(B) and combined temperatures (C);

Fig. 14 is a theophylline calibration line.

Fig. 15 is a theophylline calibration line at 32°C (A), 42°C (B) and combined temperatures (C);

Fig. 16 is a molecular structure of theophylline and caffeine;

25 Fig. 17 are FTs of theophylline. and caffeine at 16.5 μ M, 32°C; and

Fig. 18 are FTs of theophylline and caffeine.

Fig. 19 is a caffeine calibration line at combined temperatures;

Fig. 20. is a caffeine calibration line;

5 Fig. 21 is a theophylline calibration curve in the presence of
caffeine;

Fig. 22 is an FT of imprinted NIPA hydrogel with theophylline and
caffeine;

Fig. 23 is a standard curve derived for theophylline in the presence
of caffeine;

10 Fig. 24 is an FT of imprinted NIPA hydrogel with theophylline and
caffeine;

Fig. 25 is a standard curve derived for caffeine in the presence of
theophylline;

Fig. 26 is a schematic diagram of a HPC polymer;

15 Fig. 27 is a theophylline calibration curve with HPC polymer;

Fig. 28 is a theophylline calibration curve with caffeine;

Fig. 29 is a schematic diagram of CMC polymer with antibodies;

Fig. 30 is a TNFalpha calibration curve using antibodies coupled
polymer;

20 Fig. 31 is TNF alpha calibration curve in the presence of albumin;

Fig. 32 is a schematic diagram of a dendrimer polymer;

Fig. 33 is a TNFalpha calibration curve using antibodies coupled
dendrimer polymer;

Fig. 34 is a FT of dendrimer in presence of protein.

DETAILED DESCRIPTION OF THE INVENTION

In the present description by ultrasound molecular sensor it is meant any molecule that can produce an ultrasound signal upon being appropriately excited. As used herein, ultrasound molecular sensor comprises
5 but is not limited to large organic molecules such as polymers including but not limited to hydrogel polymers such as polyacrylamide, cellulose, alginates and the like, non-hydrogel polymers and dendrimers .

By target molecule it is meant molecules capable of binding to an ultrasound molecular sensor to cause ultrasound modulations. Such target
10 molecules may include but are not limited to biological molecules such as proteins, hormones and the like.

By analyte it is meant any molecule that is determined analytically by the method of the invention. It will be appreciated that in some instances target molecules may be analytes when it is desired for example to measure their
15 concentration.

There is provided a method for ultrasound contrast enhancement using an ultrasound molecular sensor for providing contrast enhancement in ultrasound imaging and quantification of analytes.

There is provided a method for detecting and quantifying analytes
20 using ultrasound frequencies measurements. In one aspect of the invention it was advantageously discovered that when an analyte is contacted with a ultrasound molecular sensor having binding sites for the analyte there results a ultrasound molecular sensor-analyte composition that exhibits a characteristic ultrasound spectrum when excited with ultrasounds. By characteristic ultrasound
25 spectrum it is meant that the composition exhibits unique ultrasound spectral profile. Furthermore, the invention provides for the quantification of analytes using spectral bands.

The ultrasound molecular sensors that are suitable for the detection and quantification of analytes are ultrasound molecular sensors that exhibit an ultrasound spectrum upon pressure excitation by an ultrasound wave and that possess binding sites for an analyte. The nature of the binding sites will vary
5 depending on the analyte to be detected and the molecular composition of the ultrasound molecular sensor. The ultrasound molecular sensor can be treated or derivatized to incorporate analyte binding sites. The binding sites can be selected from a number of possible types such as antibodies or part thereof, proteins or part thereof, nucleic acids, carbohydrates, functional groups having specific
10 physico-chemical properties and the like. For example, a receptor protein can be coupled to the ultrasound molecular sensor thereby allowing binding of the corresponding ligand.

In another approach the binding site may be created by molecular imprinting or constrained self-assembly by incubating the ultrasound molecular
15 sensor with the ligand to produce binding sites.

The ultrasound molecular sensor may be any suitable ultrasound molecular sensor provided that it can produce an ultrasound spectrum upon excitation by an ultrasound pulse and that binding of the analyte to the ultrasound molecular sensor produces a spectrum characteristic of the presence of the
20 analyte.

In a preferred embodiment, an ultrasound molecular sensor is a hydrogel polymer such as but not limited to polyacrylamide and cellulose polymers having multiple binding sites for the analyte. Polymers may also include dendrimers.

25 Detection of the ultrasound signal from the ultrasound molecular sensor or ultrasound molecular sensor-analyte complex requires excitation to induce vibrations in the ultrasound molecular sensor capable of producing ultrasound waves. In a preferred embodiment the excitation is provided by

ultrasounds, preferably a pulsed ultrasound. Ultrasounds can be detected in the transmission or the reflection configuration. Choice of the configuration can be made based on the nature of the sample to be analyzed. Liquid solutions are amenable to transmission detection but detection within an individual for example
5 may require the use of reflection configuration.

In one embodiment transmission measurements are performed using a pulsed ultrasound generated at a transducer to excite the ultrasound molecular sensor-analyte complex into high frequency vibrations which in turns generate ultrasounds that are detected using a second transducer. The
10 transducers preferably operate at between 1 and 10 MHZ. But it will be appreciated that the actual frequency of excitation depends on the type of ultrasound molecular sensor and the depth at which the ultrasound molecular sensor-analyte complex is located relative to the transducer.

Typically, as used for example in ultrasound imaging, the
15 transducer sends out a fundamental beam and receives essentially the same frequency range back as an echo (or as a transmission signal in case of transmission geometry). However, the sound wave becomes distorted as the tissue or the molecular complex expands and compresses in response to the wave. When a certain energy level is reached, this distortion results in the
20 generation of additional frequencies, called harmonics, that are two, three or more times the emitted frequency. The harmonic frequencies return to the transducer together with the fundamental frequency. In the present invention it has been discovered that enharmonic frequencies (frequencies other than the harmonic frequencies) are useful in the detection and quantification of analytes.

25 As mentioned above, it was advantageously discovered that the intensity of some of the frequency bands in the ultrasound spectrum is proportional to the concentration of the analyte. Thus the method also provides for the quantification of the analyte using one or more frequency bands that are shown to correlate with the concentration of the analyte. The quantification of an

analyte in a solution of unknown concentration can be done by establishing a standard curve, by using an internal standard or by establishing a linear combination of several frequencies to obtain an equation that computes the concentration of an analyte.

5 Thus the process of detecting or quantifying an analyte using the method of the present invention may comprise contacting the analyte with an appropriate ultrasound molecular sensor having analyte binding sites and obtaining an ultrasound signal at one or more frequencies to detect or quantify the analyte. For detecting the presence of an analyte the ultrasound signal is
10 inspected for its modulation content. By modulation it is meant the presence or absence of signal at certain frequencies, the intensity of the frequencies, frequency shifts and the like. It will be appreciated that when an analyte is analyzed for the first time it may be necessary to acquire an ultrasound signal comprising multiple frequencies to enable comparison with the spectrum of the
15 agent without analyte and therefore identify by comparing the spectra, the frequencies that are characteristic of the presence of the analyte. While a single frequency may provide enough modulation to identify an analyte, in some cases the relative intensity of two or more frequencies is necessary to distinguish between analytes. The use of multiple frequencies may also increase the
20 reliability of the detection. For quantification of a known analyte it may be possible to use a single frequency the amplitude of which has been shown to correlate with the concentration of the analyte. However establishing a correlation using a linear combination may provide more accurate results.

25 In another embodiment, changes in the ultrasound signal (acoustic properties) of a ultrasound molecular sensor, with or without the presence of an analyte, may be caused for example by changes in the conformational folding of the ultrasound molecular sensor and/or its rigidity. Thus molecular changes in the ultrasound molecular sensor may result in changes in acoustic properties. For example, it may be possible to detect the presence of reactive molecules, for

example free radicals, such as nitric oxide because of their degrading effect on the molecular structure of the ploymer. It will be appreciated that ultrasound molecular sensors may be designed to be sensitive to such molecules.

Various ultrasound molecular sensors may be used for the
5 detection of an analyte each ultrasound molecular sensor exhibiting a characteristic spectrum. Similarly a ultrasound molecular sensor may be capable of binding different analytes to generate characteristic spectra. When spectra of different analyte obtained with the same ultrasound molecular sensor are compared, similarity can indicate similarities in the analyte structure. Thus the
10 method of the invention may also be used to identify or help in the identification of unknown analytes.

The ultrasound molecular sensor of the invention can be used in a variety of ways. By way of examples they can be used for detection and quantification of analyte in mixtures. This particular application is useful in
15 chemistry, environmental analyses and the like. By selecting a biocompatible ultrasound molecular sensor, it can be used to detect and quantify analyte within a subject such as a human. Furthermore it can also serve as a contrast agent by biding analytes (or more generally molecules) that are found in specific anatomical structures.

20 Thus the ultrasound molecular sensor can be used *in vivo* for the detection of an analyte. When use in an animal or human body the ultrasound molecular sensor ultrasound agent of the invention can be injected by methods that are well known in the art such as aerosol inhalation, injection and ingestion. Preferably, the ultrasound molecular sensors of the present invention are
25 administered to a subject by subcutaneous (s.c.), intraperitoneal (i.p.), intra-arterial (i.a.), or intravenous (i.v.) injection. The ultrasound molecular sensor is also preferably administered using a pharmaceutically acceptable carrier which can be sterilized by techniques known to those skilled in the art. Pharmaceutically acceptable carrier are known to those skilled in the art and may

- 12 -

include saline solutions, liposomal preparation and the like. Samples may also be obtained from individuals and analytes measured directly in the sample.

The ultrasound molecular sensor-analyte complex will exhibit variable diameters depending on the actual composition and concentration as well as the physico chemical conditions. It will be appreciated that the size of the ultrasound molecular sensor and the ultrasound molecular sensor-analyte complex as well as its molecular composition can influence the pharmacodynamic properties of the compound. By pharmacodynamic properties it is meant the biodistribution of the compound as well as properties such as kinetics of clearance from blood or excretion from the kidney, stability and the like. One of skills in the art can optimize the composition so as to fully exploit the advantages of the invention.

Some examples of the possible *in vivo* use of the invention are detection/quantification of drugs, detection/quantification of physiological molecules (hormones, protein, vitamins and the like), temperature detection within organs (using phase transition properties of the ultrasound molecular sensor).

In another aspect of the invention there is also provided an apparatus for obtaining ultrasound measurements from various samples. The apparatus comprises ultrasounds emitting and detecting transducers that can be controlled to emit and detect at a predetermined frequency or range of frequencies. The apparatus further comprises analyzer/processor to identify/record the ultrasound signal as a function of frequency. The analyzer/processor may also comprise means to identify or distinguish between harmonic and enharmonic frequencies. In a preferred embodiment the apparatus also comprises a processor for calculating the concentration of analyte based on the ultrasound signal. The apparatus may function in the transmission or reflection mode depending on the sample being analyzed. Transmission configuration may be used for samples such as aqueous solutions while

- 13 -

reflection is more suitable for obtaining measurements from an animal such as a human.

The present invention will be more readily understood by referring to the following examples which are given to illustrate the invention rather than to
5 limit its scope.

EXAMPLES

Example 1

Certain polymer gels respond to external stimuli, in the form of changes in the surrounding environment. Temperature, pH, solvent
10 concentrations, type of solvent, electric fields, and light are a few parameters that can cause these polymer gels to change their characteristics when adjusted. N-isopropylacrilamide (NIPA) is one such polymer gel (Fig. 1), also known as a hydrogel, and it has been extensively studied due to its unusual properties.

This particular hydrogel can undergo an impressive large reversible
15 change in volume and properties when temperature is increased beyond a critical point. This critical temperature, T_c , was investigated by Shibayama and Tanaka and found to be 34°C. Below T_c , the hydrogel is a clear, transparent solution, with a viscosity similar to that of water. At the molecular level, its configuration takes the form of a swollen network of interconnected polymer chains, with
20 solvent molecules flowing freely between them.

Once the hydrogel is heated above T_c , the swollen network collapses to form small domains of concentrated polymer chains (Fig. 2) of a broad size distribution. As a result, the hydrogel solution becomes populated with an non-homogeneous mixture of lightly and heavily cross-linked regions, as
25 some areas collapse more than others. The process of undergoing this collapse is known as a phase transition, or more technically, spinodal decomposition, the onset of which is the change from transparent to turbid.

- 14 -

The spatial inhomogeneity present in the collapsed phase not only causes the solution to become turbid, scattering visible light, but also changes many properties of the hydrogel, including ultrasonic characteristics, as discussed a later section. It is also interesting to note that if the temperature is increased at an extremely slow rate (0.1°C per day), the sample becomes unquenched. Consequently, the small domains present in the solution will have enough time to diffuse, and the polymer network equilibrates, demonstrating very similar properties seen with a temperature below T_c . This is evident when considering slow movements of the small domains caused by small concentration gradients. Once the gradients have diffused completely, the gel is homogeneous and transparent, similar to its state at room temperature.

The hydrogen bonds that keep the gel swollen at room temperature become overpowered by thermal energy. Interactions between the polymer chains are therefore more prominent, causing the gel to collapse on itself. The volume inside the domain is initially constant (isochore) since solvent molecules are trapped inside during the collapse.

These properties of NIPA have generated many applications such as shape memory gels, where a modulated polymer synthesis technique was invoked to develop gels that change from a rod-like shape to various complex forms. Other interesting functions for NIPA include a thermally responsive attenuator for ultrasound waves, an optical switch, and photoresistive artificial muscles.

It is also worth noting that hydropropyl cellulose (HPC) seems to exhibit properties similar to NIPA, although the phase transition is not visually as pronounced.

Example 2

The procedure for synthesizing the NIPA hydrogel was adapted from Hu's work. N-isopropylacrylamide (NIPA, 2 g) and N,N'-methylene-bis-

- 15 -

acrylamide (MBA, 0.033 g) were added to a flask containing roughly 50 mL of water, and the resulting solution stirred until complete dissolution. Since any trace of oxygen can ruin the polymerization step, oxygen removal was accomplished by blowing nitrogen over the solution as it was turned by a
5 customized rotary evaporator (Fig. 3). In order to prevent the solution from evaporating under the constant stream of nitrogen, it was first bubbled through a flask of water. This method was found to be more efficient than simply bubbling nitrogen through the solution, taking a mere 3 hours instead of purging overnight.

Once purging was complete, tetramethylethylenediamine (TMED,
10 60 μ L) was added to the solution as the polymerization accelerator. Ammonium persulfate ((NH₄)₂S₂O₈, 0.015 g) was then introduced to initiate the radical polymerization, and the mixture was gently stirred. After about 20 minutes of settling, the solution turned slightly cloudy white denoting the presence of the NIPA hydrogel. Heating the solution to 45°C induced a phase transition, and the
15 solution turned cloudy white.

If too much water was added at the beginning, the polymerized solution might still be colorless transparent even though the polymerization was successful. Applying heat to induce a phase transition as noted above will confirm the presence of the hydrogel, as the solution should still turn opaque
20 white, although to a lesser degree.

Example 3

The procedure for synthesizing the HPC hydrogel is as follows: Hydropropyl cellulose (0.1 g) was added to a flask containing 100 mL of water. This solution's pH was adjusted to 12 through the addition of potassium
25 hydroxide (KOH), and the mixture was stirred in darkness for 4 days.

After this time elapsed, dodecyltrimethyl-ammonium bromide (DTAB, 0.35 g) was added to the solution and stirred for an additional hour. Divinylsulfone (DVS, 0.04 g) was added to the flask and the contents were

- 16 -

heated to 55°C for 30 seconds to initiate the polymerization. The solution was then quickly acidified with concentrated hydrochloric acid (HCl) to stop the polymerization.

Example 4

5 One aim of this experiment was to acquire ultrasound scans at temperatures above and below T_c for the NIPA hydrogel to characterize its ultrasonic properties.

10 The entire ultrasound system used in this experiment consisted of a 5 MHz clinical ultrasound transducer, a sample cell, a signal pulse generator / amplifier (Panametrics Inc.), an SDS 200 oscilloscope (SoftDSP Co.), a thermocouple temperature sensor connected to a multimeter, and a computer.

 The sample cell consisted of a flow cell modified in order to have full contact between the hydrogel samples and the clinical probe, for proper water-coupling to occur (Fig. 4).

15 As illustrated in the above figure, this modified cell did not have heating capabilities. Consequently, the solutions were heated in a water bath to 65°C, transferred to the sample cell with a loss of roughly 10-15°C, and data was recorded every 30 seconds as they cooled to 28°C.

20 The same ultrasound transducer was used to pulse the hydrogel samples and record the data, thereby measuring reflectance signals. This ultrasound data was acquired by the oscilloscope at a sampling rate of 12.5 MHz, no signal damping, and 128 averages per scan using SoftDSP's Softscope acquisition program. MatLab was used to import the data and perform data processing, such as constructing Fourier transforms and boxcar smoothing the data. The results of the reflectance measurements, summarized in Fig. 5 A and B show the expected sharp signal attenuation at 34°C for the NIPA hydrogel, which is consistent with Hu's work.

- 17 -

The second study aimed to further explore the ultrasonic characteristics of both NIPA and HPC hydrogels. This was achieved by rearrangement one experimental parameter, in this case, pulsing the samples with a 2 MHz clinical ultrasound probe and receiving the signal with the previously used 5 MHz probe, which measures transmission data. Acquisition parameters were left unchanged from the first study.

The results of the scans provided much more modulation than the reflectance measurements, as shown in Figs. 6 A and B and 7 A and B. This data was smoothed as previously done, and mean centered so that only changes in frequency amplitudes were made visible.

Both hydrogels showed multiple ultrasound frequency interactions as a result of undergoing a phase transition. Frequency shifts were clearly visible, demonstrated by frequency attenuation in certain places, and frequency amplification in others. Another interesting result is that while harmonic interactions were noted (harmonic denoting multiples of the pulsing frequency), enharmonic interactions were also displayed. This is emphasized to a greater extent when looking at the amplitudes of just a few frequencies over the range of temperatures.

These experiments concluded that it was possible to detect a hydrogel's phase transition by monitoring its ultrasonic properties using both reflectance and transmission measurements. The frequency shifts illustrated by the transmission measurements show both harmonic and enharmonic shifting, providing more modulation than reflectance measurements.

Example 5

The next step required the generation of a molecularly sensitive hydrogel, and test whether various concentrations of the template molecule could be detected with the clinical ultrasound system. Theophylline was chosen as the template molecule. Methacrylic acid (MAA) was deemed appropriate for the

- 18 -

implementation of binding sites in the hydrogel, since according to work done by Seitz and Lavine, there are several sites on theophylline that attract MAA (Fig. 8).

The synthesis was achieved through a slight modification of the procedure. The procedure to molecularly imprint NIPA polymer with theophylline is the following: We added 1.0 g of NIPA monomer, 0.08 g of N,N'-methylene-bis-acrylamide (MBA), 0.08 g methacrylic acid (MAA), and 0.18 g theophylline to 99 mL of distilled water (dH₂O) to form a homogeneous 1 wt % NIPA solution with stirring over 3 h to ensure complete dissolution. Oxygen in the solution was purged with nitrogen gas. We then added 15 mg of ammonium persulfate to initiate the polymerization and 60 µL of tetramethylethylenediamine as an accelerator. The solution was left to polymerize for 30 minutes with gentle stirring. Once the imprinted hydrogel was formed, the theophylline template was removed by successive methylene chloride extractions. The extraction of theophylline was confirmed spectroscopically at 271 nm. All chemicals were purchased from Sigma-Aldrich (Ontario, Canada). (See schematic structure in Figure 9). The remainder of the synthesis was carried out in the same manner as the non-imprinted NIPA.

Once the hydrogel had successfully formed, removal of the theophylline template from the imprinted NIPA hydrogel was required. This was done by transferring the hydrogel solution to a separatory funnel, and adding 15-20 mL of methylene chloride (CH₂Cl₂) (Figure 10). Methylene chloride is a useful solvent to use for the extraction, since it is already employed in the separation of caffeine for other applications.

Upon multiple vigorous agitations and careful venting, the entire contents of the funnel appeared opaque white. Allowing the contents to settle overnight, two distinct layers formed, a transparent upper water layer containing the imprinted NIPA hydrogel, and a lower opaque white layer containing methylene chloride and theophylline. The lower layer was drained off to isolate the imprinted NIPA hydrogel.

- 19 -

If the lower layer was too thick to drain efficiently, the upper layer was removed using a large volume pipette. After successful separation of imprinted NIPA and theophylline template, heat was applied to 45°C to verify that a phase transition does indeed occur.

5 Example 6

A new aluminum sample cell was designed and constructed for this experiment, and a wideband 10 MHz ultrasound probe was purchased (Optel Inc.). Mighty-Watt Cartridge heaters (Ogden Manufacturing Co.) and a temperature controller were added to the new experimental setup (Fig. 11) to more accurately control the sample cell temperature.

The external standards method was chosen to construct a theophylline calibration curve using the imprinted NIPA hydrogel, since the sample matrix, milli-q water, was easily reproducible. Each external standard had 7 mL of imprinted NIPA in water, as well as a specific amount of 0.1054 g / 100 mL theophylline stock ranging from 5 µL to 200 µL. This translates to a theophylline concentration range of 4.1 to 162.5 µM.

The limitations of the SoftScope program necessitated the oscilloscope software development kit from SoftDSP, and to create software specifically for this experiment. The data acquisition program was coded in C++, and was constructed to accept acquisition parameters from MatLab. Consequently, a MatLab user interface was created to set and change acquisition parameters, as well as load and process the ultrasonic data returned by the C++ program.

The standards were pulsed with the 2 MHz clinical probe, and the signal acquired using the new wideband 10 MHz probe. Instead of scanning through a range of temperatures as in the first part of the project, the samples were scanned at 32°C, 38°C, and 42°C. This was repeated three times at these three different temperatures, for a total of nine scans per standard. Finally, a

- 20 -

sampling rate of 12.5 MHz was used, with no signal damping, and 1500 averages per scan. A sample Fourier transform of the results is given in Fig. 12.

These Fourier transforms were normalized with respect to the area under each curve and were fed into a stagewise multilinear regression (MLR) script for Matlab, programmed to select three wavelengths for the calibration equation. This tool iteratively calculated each regression possibility, and returned the best multilinear fit. The easiest way to visualize how well the multilinear fit coincides with the data is to view a plot of the estimated theophylline concentration from MLR, against the actual theophylline concentration of the standards. These comparisons are shown for the data acquired at 32°C, 42°C, and the combined data over the three acquisition temperatures (Fig. 13 A, B and C). The data at 38°C is not shown as it was very similar to that taken at 42°C. It was however, included in the combined temperature analysis. A further calibration curve is shown in Figure 14.

These results indicate that theophylline concentrations changes were detected using the imprinted NIPA hydrogel, with exceptional accuracy. It was also evident from these results that temperature was not a significant factor in determining the concentration of a theophylline solution using the imprinted NIPA hydrogel.

The experiment was repeated a second time to ensure reproducibility. This time the concentration range was extended to include theophylline concentrations of 1.7 to 162.5 µM, including a blank measurement with no theophylline. This essentially covered a magnitude change of nearly 100. The data acquisition conditions were kept identical to the first experiment, and the results processed in the same manner. Fig. 15 A, B and C shows the data acquired at three previously mentioned temperatures, as well as the combined data at all temperatures.

The frequencies selected by the MLR for each temperature are shown below. The equation to calculate the concentration of theophylline based on the amplitudes at these frequencies is shown below.

Table 1 MLR Frequencies Chosen for Theophylline at Each Temperature

5

	32°C	42°C	Comb'd Temperatures
1st Frequency	5.2 MHz	4.2 MHz	5.2 MHz
2nd Frequency	8.2 MHz	7.6 MHz	8.2 MHz
3rd Frequency	7.0 MHz	5.3 MHz	5.5 MHz

MLR Calibration Equations for Theophylline at Each Temperature

$$\begin{aligned} \text{Conc @ 32°C} &= (0.26 \times 10^6) \cdot \text{Amp}_{\text{Freq 1}} - (3.29 \times 10^6) \cdot \text{Amp}_{\text{Freq 2}} + (0.39 \times 10^6) \cdot \text{Amp}_{\text{Freq 3}} - 200 \\ \text{Conc @ 42°C} &= (9.61 \times 10^5) \cdot \text{Amp}_{\text{Freq 1}} + (5.99 \times 10^5) \cdot \text{Amp}_{\text{Freq 2}} + (6.97 \times 10^5) \cdot \text{Amp}_{\text{Freq 3}} - 0.02 \times 10^5 \\ \text{Conc @ Comb. T.} &= (0.72 \times 10^6) \cdot \text{Amp}_{\text{Freq 1}} - (5.66 \times 10^6) \cdot \text{Amp}_{\text{Freq 2}} - (0.07 \times 10^6) \cdot \text{Amp}_{\text{Freq 3}} + 80 \end{aligned}$$

The calibration experiment again concluded that it is possible to quantify theophylline concentrations using the imprinted NIPA hydrogel. These results also seem to be largely independent of temperature, as well as being reproducible.

15

Example 7

Caffeine and theophylline share almost identical chemical structures, with the exception of one methyl group and the placement of one π -bond (Fig. 16). This makes caffeine ideal for selectivity studies, as there are few other readily available compounds that are as similar to theophylline. The goal of this study was to see if the theophylline imprinted NIPA hydrogel was also sensitive to caffeine.

20

- 22 -

An external standards experiment was devised in the same fashion as for theophylline, except that the caffeine concentration range extended from 16.5 to 65.3 μM , including a blank measurement with no caffeine. The data was acquired using the same parameters as the for the theophylline calibration study.

5 Upon first inspection of the normalized Fourier transforms, there is a subtle difference in normalized spectral profile between theophylline and caffeine of similar concentration (Fig. 17 and 18). This denotes that certain frequencies are a little more pronounced for one compound than the other.

10 The next step was to quantify the different frequency profiles for both compounds. This was determined by calculating the concentrations of the caffeine standards for the averaged temperature data, using the theophylline calibration equation and the amplitudes at frequencies selected for theophylline. The table listed below shows the results of these calculations.

Table 2 - Table of Calculated and Actual Caffeine Concentrations

15

Calculated Caffeine Concentrations	174.4 μM	161.0 μM	93.6 μM	253.8 μM
Actual Caffeine Concentrations	0.0 μM	16.5 μM	32.8 μM	65.3 μM

20 It is evident that the amplitudes at the frequencies chosen for theophylline cannot be used to reliably calculate the concentration of caffeine. However, when the caffeine data was fed into the stagewise MLR program, a calibration equation was obtained. A comparison of calculated and actual caffeine concentrations showed that this equation was extremely accurate. This is due to the fact that the MLR program chose different frequencies to calculate the caffeine concentration than for theophylline. The frequencies selected when data from the three temperatures were averaged are **5.7 MHz**, **6.5 MHz**, and **4.2**

- 23 -

MHz, from the most to least significant, which are quite different than those chosen for theophylline. The calibration equation is given below.

MLR Calibration Equation for Caffeine at Combined Temperatures

$$5 \quad \text{Conc. Avg. T.} = (1.32 \cdot 10^5) \cdot \text{Amp}_{\text{Freq } 1} - (1.45 \cdot 10^5) \cdot \text{Amp}_{\text{Freq } 2} + (1.06 \cdot 10^3) \cdot \text{Amp}_{\text{Freq } 3} - 380$$

This experiment indicates that the theophylline imprinted NIPA hydrogel is not totally theophylline selective. Nevertheless, theophylline selectivity is still achieved through the careful selection of frequencies for the analysis. These frequencies have been shown to differ from those chosen for caffeine, so a simultaneous analysis of both theophylline and caffeine is theoretically highly possible.

Calibration curves for caffeine are shown in figure 19 and 20 and for theophylline in the presence of caffeine in figure 21.

It is possible to distinguish and quantify an analyte in a mixture of analytes using a single agent. This is illustrated in Fig. 22-25. In Fig 22 a spectrum of an imprinted NIPA hydrogel in the presence of theophylline and caffeine is shown. Frequencies were derived that were used to establish a calibration curve for theophylline in the presence of caffeine (Fig. 23). The same experiment was performed to establish a caffeine calibration curve in the presence of theophylline (Fig. 24, 25). As can be seen the results demonstrate a very good correlation between estimated and actual concentration, clearly indicating that an analyte can be quantified in the presence of other analytes.

Example 8

Similar experiments were carried out using hydroxypropyl cellulose polymer (Figure 26). The procedure to crosslink HPC is based on work by Liao et al. 1 g of HPC powder and 0.1 g of theophylline were added to 48.9 g of dH₂O

- 24 -

and stirred for 3 days to form a homogenous 1 wt % solution of HPC with 20mM of theophylline. 40 μ L of divinylsulphone (DVS) were then added to the solution. After 3 hours of stirring, 5 drops of 1 M Sodium Hydroxide were added to the solution to raise the pH to approximately 12. The cross-linking reaction was
5 allowed to continue for 5 hours.

The crosslinked polymers were then dialyzed against distilled water for 3 days to remove the theophylline, sodium chloride, and any free DVS.

10 Figure 27 shows a calibration curve of theophylline. Caffeine was used as an interfering species owing to its chemical structure being nearly-identical to theophylline.

Five sets of molecularly imprinted HPC solutions were prepared.
15 Each set had a unique concentration of caffeine and the concentration of theophylline was varied across solutions. Likewise, the concentration of caffeine was increased from one set to another, spanning 0 to 10 mM (figure 28

This data shows that it is possible to determine the concentration of
20 theophylline using the molecular imprinting of the HPC polymer in the presence of caffeine.

Example 9

The procedure to couple CMC and the TNF α antibody is based on
25 work by Wheatley et al. 0.5 g of CMC powder and 0.84 g NaCl were added to 49.5 g of 0.1 M phosphate buffer, pH 6.5, and stirred for 3 days to form a homogenous 1 wt % solution of CMC. 5 mg of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) and 3 mg of N-hydroxy-succinimide (NHS) were then added to the solution and mixed for 15 minutes.

Following this, 20.6 pmol of TNF α antibodies were added to the mixture and the coupling was allowed to take place over 3 hours. The polymers were then dialyzed for 2 days to remove any unreacted coupling agent and finally the pH was adjusted to 7.4 (physiological pH) (Figure 29).

5

This project relies on the molecular recognition sites in the antibodies rather than recognition in the cellulose polymer. Antibodies are proteins, or long chains of amino acids, that are biosynthesized and have very specific antigen-recognition sites with binding constants typically in the nM⁻¹ range. These are coupled to the cellulose by the EDC mentioned above.

10

Figure 30 shows that it is possible to determine the concentration of the protein, TNF α , using the CMC that has been coupled to the TNF α antibodies.

15

Figure 31 demonstrates the applicability of the antibody-coupled CMC sensor in biological/*in vivo* conditions. It is possible to determine the concentration of the protein, TNF α , in the presence of physiological concentrations of serum albumin, which is the most abundant protein in blood, as well as a physiological pH.

20

We have used a non-cellulose dendrimer for this work (figure 32). These polymers form very regular spheres onto which antibodies are attached.

The procedure used to couple the antibodies to the PAMAM dendrimer is identical to that used in coupling CMC and antibodies with the exception that a 0.01 wt % gel was made (rather than a 1 wt % CMC gel, above).

25

Figure 33 shows that it is possible to determine the concentration of the protein, TNF α , using the PAMAM dendrimer that has been coupled to the TNF α antibodies.

5 Figure 34 demonstrates what we believe to be a characteristic change in frequencies observed when the antibody-coupled dendrimer binds to the protein, TNF α .

10 While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosures as come within
15 known or customary practice within the art to which the invention pertains and as may be applied to the essential features herein before set forth, and as follows in the scope of the appended claims.

CLAIMS:

1. A method for ultrasound contrast enhancement, comprising:
 - providing an ultrasound molecular sensor comprising one or more target binding sites for binding one or more target molecules, said ultrasound molecular sensor having target-bound and target-unbound states wherein binding of said one or more target molecules to said ultrasound molecular sensor causes a modulation in an ultrasound signal;
 - contacting said ultrasound molecular sensor with said one or more target molecules to produce ultrasound molecular sensor in the target-bound state; and
 - obtaining an ultrasound signal of the target-bound ultrasound molecular sensor at one or more ultrasound frequencies wherein the signal comprises a modulation indicative of the presence of at least one target molecule.
2. The method of claim 1, wherein the signal is indicative of the amount of the at least one target molecule present.
3. The method as claimed in claim 1 or 2 wherein the modulation is a relative intensity value of two or more frequencies.
4. The method as claimed in any one of claims 1 to 3 wherein the modulation is a shift in one or more frequencies.
5. The method as claimed in any one of claims 1 to 4 wherein the one or more frequencies comprise enharmonic frequencies.
6. The method as claimed in any one of claims 1 to 5 wherein the one or more frequencies are comprised between 1-10Mhz.
7. The method as claimed in any one of claims 1 to 6 further comprising quantifying the one or more target molecule.

8. The method as claimed in claim 7 wherein the quantifying comprises establishing a standard curve using signal amplitude of at least one frequency characteristic of the presence of the target molecule.
9. The method as claimed in claim 7 wherein the quantifying comprises establishing a linear combination of signal amplitude at multiple frequencies that correlates with concentration of the target molecule.
10. The method as claimed in any one of claims 1 to 9 wherein the target molecule binding sites are selected from an aptamer, antibody, variable regions of antibody, receptor, nucleic acids, protein or part thereof, carbohydrates, molecular imprints and combinations thereof.
11. The method as claimed in any one of claims 1 to 10 wherein two or more target molecules are simultaneously detected.
12. The method as claimed in claim 11 wherein two or more ultrasound molecular sensors are used to detect the target molecules.
13. The method as claimed in any one of claim 1-12 wherein the detection of the target molecule is *in situ*.
14. The method as claimed in claim 13 wherein said *in situ* detection is *in vivo* or *in vitro*.
15. The method as claimed in any one of claim 1-14 wherein said detection is performed in a sample obtained from a subject.
16. The method as claimed in claim 15 wherein said sample is a blood sample.
17. The method as claimed in claim 13 or 14 wherein the ultrasound molecular sensor is administered to a subject for detection of a target molecule in the subject.

18. The method as claimed in claim 17 wherein said administration is selected from either of enteral and parenteral.
19. The method as claimed in claim 18 wherein the parenteral administration is selected from subcutaneous (s.c.), intraperitoneal (i.p.), intra-arterial (i.a.), and intravenous (i.v.) injection.
20. The method as claimed in any one of claims 1 to 19 wherein the ultrasound molecular sensor is a polymer.
21. The method as claimed in claim 20 wherein the polymer is a hydrogel polymer.
22. The method as claimed in claim 21 wherein the hydrogel polymer is selected from polyacrilamide, cellulose and alginates.
23. The method as claimed in claim 20 wherein the polymer is a dendrimer.
24. The use of a ultrasound molecular sensor for ultrasonic detection of a target molecule.
25. The use as claimed in claim 24 wherein the ultrasound molecular sensor is a polymer.
26. The use as claimed in claim 25 wherein the polymer is a hydrogel polymer.
27. The use as claimed in claim 25 wherein the hydrogel polymer is selected from polyacrilamide, cellulose and alginate.
28. The use as claimed in claim 25 wherein the polymer is a dendrimer.
29. The use as claimed in any one of claims 24 to 28 wherein said target molecule is in a subject.
30. A compound comprising a ultrasound molecular sensor and analyte binding sites coupled to the ultrasound molecular sensor; said compound having target-bound and target-unbound states, wherein said target-unbound

- 30 -

state is substantially transparent to ultrasound and said target-bound state is ultrasound sensitive, and wherein the analyte binding sites are in sufficient number for producing a detectable ultrasound signal at characteristic frequencies when molecules of analytes are bound to the analyte binding sites, thereby causing said compound to be in a target-bound state.

31. The compound as claimed in claim 30 wherein the analyte binding sites are produced by molecular imprinting.

32. The compound as claimed in claim 30 or 31 wherein the analyte binding sites are selected from aptamer, antibody, variable regions of antibody, receptor, nucleic acids, protein or part thereof, carbohydrates, molecular imprints and combinations thereof.

33. The compound as claimed in any one of claims 30 to 32 having a diameter of between about 10 nanometers to about 1000 microns.

34. A composition comprising the compound of any one of claims 30 to 33 and a medium in which the compound is dispersed.

35. A method for detecting an analyte, comprising:

- contacting the analyte with an ultrasound molecular sensor comprising one or more analyte binding sites for binding one or more analytes, said ultrasound molecular sensor having analyte-bound and analyte-unbound states wherein binding of said one or more analyte to said ultrasound molecular sensor causes a modulation in ultrasound signal;; and
- obtaining an ultrasound signal of the analyte-bound state at one or more frequencies wherein the signal comprises modulation indicative of the presence of the analyte.

36. The method of claim 35, wherein the signal is indicative of the amount of the analyte.

37. The method as claimed in claim 35 or 36 wherein the modulation is a relative intensity value of two or more frequencies.
38. The method as claimed in any one of claims 35 to 37 wherein the modulation is a shift in one or more frequencies.
39. The method as claimed in any one of claims 35 to 38 wherein the one or more frequencies comprise enharmonic frequencies.
40. The method as claimed in any one of claims 35 to 39 wherein the one or more frequencies are comprised between 1-10Mhz.
41. The method as claimed in any one of claims 35 to 40 further comprising quantifying the analyte.
42. The method as claimed in claim 41 wherein the quantifying comprises establishing a standard curve using signal amplitude of at least one frequency characteristic of the presence of the analyte.
43. The method as claimed in claim 41 wherein the quantifying comprises establishing a linear combination of signal amplitude at multiple frequencies that correlates with concentration of the analyte.
44. The method as claimed in any one of claims 35 to 43 wherein the analyte binding sites are selected from an aptamer, antibody, variable regions of antibody, receptor, nucleic acids, protein or part thereof, carbohydrates, molecular imprints and combinations thereof.
45. The method as claimed in any one of claims 35 to 44 wherein two or more analytes are simultaneously detected.
46. The method as claimed in any one of claims 35 to 45 wherein two or more ultrasound molecular sensors are used to detect the analytes.
47. The method as claimed in any one of claim 35 to 46 wherein the detection of the analyte is *in situ*.

48. The method as claimed in claim 47 wherein said *in situ* detection is *in vivo* or *in vitro*.

49. The method as claimed in any one of claim 35-48 wherein said detection is performed in a sample obtained from a subject.

50. The method as claimed in claim 49 wherein said sample is a blood sample.

51. The method as claimed in any one of claims 35-48 wherein the ultrasound molecular sensor is administered to a subject for detection of an analyte in the subject.

52. The method as claimed in claim 51 wherein said administration is selected from either of enteral and parenteral.

53. The method as claimed in claim 52 wherein the parenteral administration is selected from subcutaneous (s.c.), intraperitoneal (i.p.), intra-arterial (i.a.), and intravenous (i.v.) injection.

54. The method as claimed in any one of claims 35 to 53 wherein the ultrasound molecular sensor is a polymer.

55. The method as claimed in claim 54 wherein the polymer is a hydrogel polymer.

56. The method as claimed in claim 55 wherein the hydrogel polymer is selected from polyacrilamide, cellulose and alginate.

57. The method as claimed in claim 54 wherein the polymer is a dendrimer.

58. The use of a ultrasound molecular sensor for ultrasonic detection of an analyte.

59. The use as claimed in claim 58 wherein the ultrasound molecular sensor is a polymer.

60. The use as claimed in claim 59 wherein the polymer is a hydrogel polymer.

61. The use as claimed in claim 60 wherein the hydrogel polymer is selected from polyacrilamid, cellulose and alginate.

62. The use as claimed in any one of claims 58 to 61 wherein said analyte is in a subject.

63. An apparatus for ultrasound detection of an analyte-ultrasound molecular sensor complex the apparatus comprising:

- i) a transducer to generate an ultrasound pulse;
- ii) a transducer to detect ultrasounds; and
- iii) means to identify ultrasound frequencies emitted by the analyte-ultrasound molecular sensor complex.

64. The apparatus as claimed in claim 63 wherein the apparatus further comprises means to calculate concentration of analyte.

65. The apparatus as claimed in claim 63 or 64 further comprising means to identify harmonic and enharmonic frequencies.

66. The apparatus as claimed in any one of claims 63 to 65 further comprising means to compare relative intensities of two or more frequencies.




FIGURE 1




FIGURE 2




FIGURE 3










FIGURE 4

A.**B.****FIGURE 5**

**FIGURE 6**

**FIGURE 7**

**FIGURE 8**











FIGURE 9

**FIGURE 10**


**FIGURE 11****FIGURE 12**


**FIGURE 13**

**FIGURE 14**


A.**B.**

Combined Temperatures
 $R^2 = 0.999$


C.**FIGURE 15**




Theophylline



Caffeine

FIGURE 16**FIGURE 17**

**FIGURE 19**





FIGURE 20

**FIGURE 21**

Imprinted NIPA Hydrogel with 8.3 μM Theophylline and 4.1 μM Caffeine at Combined Temperatures




FIGURE 22

Theophylline Calibration Line at Combined Temperatures in the Presence of Caffeine




FIGURE 23

Theophylline Calibration Line at Combined Temperatures in the Presence of Caffeine




FIGURE 25

**Theophylline concentrations determined using frequencies from MLR
and Leave-One-Out Cross Validation (CV)**




FIGURE 27

Theophylline concentrations in samples doped with varying concentrations of caffeine




FIGURE 28

Carboxymethyl Cellulose (CMC) affixed with TNF- α antibodies

- Selective molecular "pockets" designed by biological systems!




FIGURE 29

TNF α concentrations determined using frequencies from MLR and CV




FIGURE 30

Estimated vs. known TNF α concentration in the presence of albumin
using MLR and CV




FIGURE 31

- **Increasing monodispersity should improve sensitivity**

→ Dendrimers have well-controlled polymeric structure

- **Poly-amidoamine dendrimers are biocompatible⁵**

→ Same antibody linking procedures





FIGURE 32

**TNF α concentrations determined using frequencies from MLR and
Leave-One-Out Cross Validation (CV)**




FIGURE 33

■ Difference in frequencies measured in the sensor cause by protein

- Shift towards higher frequencies → Stiffening of gel?




FIGURE 34

专利名称(译)	超声分子传感器及其用途		
公开(公告)号	EP1993447A2	公开(公告)日	2008-11-26
申请号	EP2007733912	申请日	2007-03-02
[标]申请(专利权)人(译)	麦吉尔大学		
申请(专利权)人(译)	麦吉尔大学		
当前申请(专利权)人(译)	麦吉尔大学		
[标]发明人	BURNS DAVID TROIANI DAVID DION JONATHAN		
发明人	BURNS, DAVID TROIANI, DAVID DION, JONATHAN		
IPC分类号	A61B6/00 A61B8/00 A61K49/22		
CPC分类号	A61K49/226 A61B8/0866 A61B8/481		
优先权	60/780823 2006-03-10 US		
其他公开文献	EP1993447A4		
外部链接	Espacenet		

摘要(译)

本发明涉及聚合物作为超声波造影剂的用途。该想法是在聚合物中具有对给定分子或分析物特异的分子印记。当该分子与聚合物结合时，它诱导构象变化，导致超声信号的增加，称为靶结合状态。该方法还可用于例如分析物的定量测量。